Role of PACAP in Nehprotic Syndrome

Role of PACAP in Increased Platelet Count and Aggregability in Childhood Nephrotic Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01411982

Enrollment

Registered

2011-08-08

Start date

2011-09-30

Completion date

2014-09-30

Last updated

2015-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrotic Syndrome

Keywords

PACAP (pituitary adenylate cyclase-activating polypeptide), Nephrotic syndrome, Thrombosis, Platelets

Brief summary

This study will identify the role of PACAP (pituitary adenylate cyclase-activating polypeptide) deficiency in patients with nephrotic syndrome. PACAP is a neuropeptide that has a putative role as an inhibitor of megakaryopoiesis and platelet function. Patients with nephrotic syndrome show decreased PACAP plasma levels, due to urinary loss. We hypothesize that in severe nephrotic syndrome, plasma deficiency of PACAP enhances megakaryopoiesis and causes blood platelet activation, which contribute to the increased rate of thromboembolic disease in these patients. To test our hypothesis, the role of PACAP deficiency on pro-thrombotic state in patients with nephrotic syndrome will be studied using patient blood and urine samples.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 18 Years

Healthy volunteers

Inclusion criteria

* New patient with nephrotic syndrome of patient during relapse of nephrotic syndrome * Under 16 years old * Treatment for nephrotic syndrome not yet started by first sample collection

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame
PACAP levels in plasma and urine	3 test moments: at baseline during nephrotic syndrome before start of treatment; 4 weeks after start of remission; 4 weeks after stop of corticosteroid treatment. Estimated total time frame: 5 months

Secondary

Measure	Time frame
Platelet aggregability	3 test moments: at baseline during nephrotic syndrome before start of treatment; 4 weeks after start of remission; 4 weeks after stop of corticosteroid treatment. Estimated total time frame: 5 months
Platelet count	3 test moments: at baseline during nephrotic syndrome before start of treatment; 4 weeks after start of remission; 4 weeks after stop of corticosteroid treatment. Estimated total time frame: 5 months

Countries

Belgium

Outcome results